Medicinal preparations containing a drug 2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole wherein the QOL and compliance of patients taking this drug can be improved and an unnecessary increase in the drug concentration in the plasma can be prevented by sustaining the release speed of the drug <i>in vivo</i> and lowering the administration frequency of the drug. That is, sustained release oral preparations containing 2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole as the active ingredient.
